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Summary Preliminary data would suggest that the pineal hormone, melatonin (MLT), may enhance
tamoxifen (TMX) anti-tumour efficacy. Both MLT and TMX have been used as single agents in the palliative
treatment ofmetastatic neoplasms, other than the classical hormone-dependent tumours, without, however, any
clear efficacy. On this basis, a phase II study with TMX plus MLT has been performed in untreatable
metastatic solid tumour patients. The study included 25 metastatic solid tumour patients other than breast
cancer and prostate cancer (six unknown primary tumour; four melanoma; four uterine cervix carcinoma; five
pancreatic cancer; three hepatocarcinoma; two ovarian cancer; one non-small-cell lung cancer), for whom no
other effective standard therapy was available, because of poor clinical conditions, no response to previous
chemotherapies and/or chemotherapy-resistant tumours. Both drugs were given orally every day until disease
progression (TMX, 20 mg day- 1 at noon; MLT, 20 mg day-lin the evening). Three patients had a partial
response (PR) (12%; 95% confidence limits 2-24%) (one cervix carcinoma; one melanoma; one unknown
primary tumour). A stable disease (SD) was achieved in 13 other patients, whereas the remaining nine patients
progressed. Performance status (PS) improved in 9/25 patients, whose median score increased from 50% to
70%. Finally, a survival longer than 1 year was observed in 7/25 (28%) patients. This phase II study would
suggest that the neuroendocrine combination with TMX plus MLT may have some benefit in untreatable
metastatic solid tumour patients, either in controlling cancer cell proliferation or improving the PS.
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According to preliminary experimental observations, many
solid neoplasms would seem to be characterised by a partial
hormone dependency, including cancer of pancreas, hepato-
carcinoma, renal cell carcinoma, gynaecological tumours and
melanoma, even though endocrine receptor expression has
still to be clinically investigated in these neoplasms. However,
classical endocrine therapy with anti-oestrogen and anti-
androgen agents is ineffective in inducing objective tumour
regressions in solid neoplasms, other than breast and prostate
cancer. Moreover, standard anti-cancer hormonotherapies
consist of an administration of anti-hormones, whereas there
are only very preliminary data concerning the possibility of
treating human neoplasms with endogenous oncostatic
hormones. At present, the most investigated endogenous
anti-tumour hormone is the pineal hormone, melatonin
(MLT) (Regelson and Pierpaoli, 1987), whose immunomo-
dulating and oncostatic properties have been well demon-
strated in experimental conditions. MLT has also improved
the clinical status of untreatable metastatic solid tumour
patients (Lissoni et al., 1991), mainly by counteracting
macrophage-mediated immunosuppression, or cachexia
(Broder et al., 1978), through inhibition of the release of
tumour necrosis factor alpha (TNF-cx) (Beutler and Cerami,
1987). Therefore, both the oncostatic and palliative effects of
MLT and other endogenous immunomodulating substances
have to be considered. In fact, whereas the well-being induced
by palliative drugs, such as steroids, is generally compromised
by undesirable biological effects, particularly the suppression
of host anti-cancer defences, the improvement in the quality
of life of advanced cancer patients achieved by MLT is
associated with an enhanced immune performance (Lissoni et
al., 1989), as well as with a potential inhibitory effect on
cancer cell proliferation, even though the evidence of
objective tumour regressions is an extremely rare phenomen-
on during therapy with MLT alone. Tamoxifen (TMX) has
been proven to have oncostatic effects in addition to its anti-
oestrogen action, such as the inhibition of tumour growth
factor secretion (Pollak et al., 1990) and the capacity for
stimulating the secretion of transforming growth factor ,B
(TGF-JJ) (Knabbe and Lippman, 1987), which has been
shown to inhibit the proliferation of several cancer cell lines.
Unfortunately, TGF-,B is one of the most effective
endogenous immunosuppressive agents, and, in particular, it
appears to counteract the anti-neoplastic action of inter-
leukin 2 (IL-2), whose importance in generating anti-tumour
cytotoxic lymphocytes is well known (Inge et al., 1992).
Preliminary clinical studies have suggested that MLT may
enhance TMX efficacy in breast cancer patients (Lissoni et
al., 1995). In addition, experimental studies have shown that
MLT may neutralise the immunosuppressive effects of several
substances, including steroidal agents and cancer chemother-
apy (Maestroni et al., 1988). An eventual abrogation ofTGF-
fl-induced immunosuppression by MLT could further amplify
the efficacy of MLT-TMX association, with potential
therapeutic implications in several tumour histotypes,
irrespective of their hormone dependency.
This preliminary phase II study was designed in an
attempt to evaluate clinical efficacy and tolerability of a
neuroendocrine strategy with TMX plus MLT in metastatic
solid tumour patients with low performance status (PS),
suffering from neoplasms other than the classical hormone-
dependent tumours.
Patients and methods
The study included 25 consecutive metastatic solid tumour
patients (M/F ratio 10/15; median age, 64 years, range 38-81
years), who were admitted to the Hospital of Monza or the
Cantonal Hospital of Locarno, and for whom no other
standard anti-neoplastic therapy was available, because of
progression on previous chemotherapies, or tumours for
which there is no effective chemotherapy, or poor PS.
Eligibility criteria consisted of histologically proven meta-
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static solid neoplasm, measurable lesions, no double tumour,
no availability of effective chemotherapy because of lack of
response to previous chemotherapies, or chemotherapy-
resistant tumours, or poor PS. Fourteen patients had
previously been treated by chemotherapy, three patients had
previously been treated by TMX, whereas the remaining eight
patients were untreated for their metastatic disease. The
median Karnofsky score was 60 (20-90). The experimental
protocol was explained to each patient, and informed consent
was obtained. TMX was given orally at a daily dose of 20 mg
at 12.00 every day until disease progression. The pineal
hormone, MLT, supplied by Helsinn Chemicals (Breganzona,
Switzerland), was given orally at a daily dose of 20 mg in the
evening on every day of TMX therapy starting 7 days before
TMX, as an induction phase. The timing of MLT
administration was established from our previous studies
(Lissoni et al., 1989) by taking into consideration its greater
biological activity in the dark period of the day. Patients
progressing on TMX alone had been off TMX for at least 1
month before starting the neuroendocrine therapy with TMX
plus MLT. Patients previously treated with chemotherapy
started MLT and TMX therapy also after at least 1 month
from chemotherapy interruption. No patient was excluded
from the study during the recruitment period.
Endocrine receptor expression was not analysed. Radi-
ological staging investigations, including computerised tomo-
graphy (CT) scan and/or magnetic resonance (MR), were
done before the onset of therapy, after each month of
treatment for the first 3 months, then every 3 months.
Clinical response and toxicity were confirmed by external
reviewers. Clinical response and toxicity were evaluated
according to UICC and WHO criteria respectively (UICC,
1978; WHO, 1976). The duration of response and the overall
survival time were calculated from the onset of therapy.
Routine laboratory tests were repeated at weekly intervals for
the first 3 months, then at 14 day intervals. Data were
statistically analysed by the chi-square test, the Student's t-
test and analysis of variance, as appropriate.
Results
The characteristics of patients and their clinical response are
shown in Table I. No complete response was seen. Partial
response (PR) was achieved in three cases (12%; 95%
confidence limits 2-24%; duration, 5, 6 and 8 months).
The first patient had multiple skin metastases caused by
melanoma, mainly at the abdominal wall; the second patient
showed abdominal node metastases as a result of uterine
cervix carcinoma, with a median diameter of 2 cm, as
assessed by MR; the third patient had multiple dorsal and
lumbar vertebral bone metastases due to unknown primary
tumour, and his response was assessed by radiographs, CT
scan and MR. Thirteen other patients (52%) had stable
disease (SD), with a median duration of 6 months (range 3-
23 months), whereas the remaining nine (36%) patients had
progressive disease (PD). All patients were followed up for at
least 1 year. Survival for longer than 1 year was observed in
7/25 (28%) patients, and the percentage of 1 year survival, as
evaluated according to the chi-square test, was significantly
higher in patients with PR or SD than in those with PD (7/16
vs 0/9, P<0.05). No toxicity was found, and in particular no
MLT-related toxicity was seen. On the contrary, most
patients experienced a relief of depressant symptoms, anxiety
and asthenia. Moreover, a clear improvement in PS occurred
in 9/25 (36%) patients, whose median score increased from
50% (range 40-80%) before therapy to 70% (range 60-
100%) on treatment.
Platelet numbers became within the normal range in 3/4
patients with cancer-related persistent thrombocytopenia, and
platelet mean number seen on treatment, as expressed as
maximum values on study, was significantly higher with
respect to the pretreatment values (136 + 14 vs 72 +8,
nx I03 mm-3, mean+s.e., P<0.01). The first patient had
multiple bone metastases due to unknown primary tumour,
while the other two patients had portal hypertension
syndrome caused by hepatocarcinoma and liver metastases
as a result of cancer of the pancreas respectively. Finally,
Table I Characteristics and clinical response of 25 metastatic solid tumour patients treated by neuroendocrine combination of tamoxifen plus
melatonin
Time to
Age Metastasis Previous Clinical progression Survival
Cases Sex (years) PS Tumour histotype sites therapya responseb (months) (months)
I M 80 80 Hepatocarcinoma Bone SD 23b 23b
2 F 75 50 Unknown primary Liver SD 11 19b
3 F 38 30 Cervix carcinoma Lung RT, POB PD - 2
4 F 56 40 Pancreatic cancer Liver 5-FU/folates SD 5 10
5 F 46 90 Melanoma Brain, skin, DTIC +IFN SD 11 16
nodes
6 M 79 20 Hepatocarcinoma Lung TMX PD 4
7 F 51 50 Cervix carcinoma Lung RT, POB PD - 4
8 F 81 60 Melanoma Skin PR 5 13
9 F 51 60 Unknown primary Bone, bone EPI SD 8 11
marrow
10 F 79 60 Cervix carcinoma Nodes RT, TMX PR 6 9
11 F 72 70 Hepatocarcinoma Lung TMX SD 8 11
12 M 58 40 Melanoma Liver, lung DTIC+IFN PD - 4
13 M 64 80 Unknown primary Bone SD 8 11
14 M 75 40 Pancreatic cancer Liver SD 3 7
15 F 39 40 Ovarian cancer Lung CDDP/DOX Taxol PD - 4
16 F 46 80 Ovarian cancer Lung, nodes CDDP/DOX Taxol SD 5 10
17 F 79 70 Melanoma Skin DTIC SD 6 13
18 M 61 90 Unknown primary Bone PR 8 13+
19 F 72 80 Unknown primary Bone, nodes CDDP/VP16 SD 4 10
20 M 54 60 Unknown primary Bone CDDP/VP16 PD - 3
21 M 74 50 Pancreatic cancer Liver PD - 3
22 M 58 60 Pancreatic cancer Nodes 5-FU SD 6 12+
23 F 72 70 Cervix carcinoma Liver 5-FU/CDDP PD - 3
24 M 64 70 Lung cancer Bone CDDP/VP16 SD 3 10
25 F 66 20 Pancreatic cancer Liver PD - I
aRT, radiotherapy; POB, cisplatin, vincristine, bleomycin; 5-FU, fluorouracil; DTIC; dacarbazine; IFN, interferon-alpha 2a; TMX, tamoxifen;
EPI, epirubicin; CDDP, cisplatin; DOX, doxorubicin; VP16, etoposide. bPR, partial response; SD, stable disease; PD, progressive disease.
1467Tamoxifen plus melatonin in advanced neoplasms
rvY wP Lissoni et al
1468
blood mean number of lymphocytes increased on therapy,
and the mean increase in lymphocyte blood counts, as
evaluated by the Student's t-test and the analysis of variance,
observed in patients with response or SD, was significantly
higher with respect to that seen in progressing patients
(536+79 vs 179+42, n mm-3, mean+s.e., P<0.05).
Discussion
Even though the low number of patients and the different
tumour histotypes do not allow us to draw definite
conclusions, this phase II study suggests that the neuroendo-
crine combination with TMX and MLT is a well-tolerated
treatment, even in patients of poor clinical status, and a
potentially active therapy to induce stabilisation of disease
and objective tumour regressions in at least a few cases in
patients unable to receive more aggressive therapies. Since
MLT alone is generally unable to induce objective tumour
regressions (Lissoni et al., 1989, 1991), this phase II study
would suggest that the concomitant administration of TMX
may amplify the oncostatic activity of MLT, perhaps
through a stimulation of TGF-f, release, even though at
present there are no data about the effect of MLT plus TMX
on TGF-,B secretion. Alternatively, MLT might amplify
TMX efficacy, as suggested by the evidence of disease
stabilisation in patients previously progressing on TMX
alone, perhaps by stimulating endocrine receptor expression
on cancer cells (Regelson and Pierpaoli, 1987). Therefore, the
results of the study may encourage examination of the
mechanism of action of the TMX-MLT combination and
performance of a randomised comparison with best
supportive care. Finally, the evidence that the neuroendo-
crine combination of TMX and MLT may improve the PS of
advanced cancer patients of poor clinical conditions would
justify successive studies by associating well-tolerated
monochemotherapies, such as low-dose epirubicin, vinor-
elbine or mitoxantrone, in an attempt to evaluate the
possibility of obtaining more interesting results without
worsening the quality of life of patients.
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